Cargando…

SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay

Dogs are occasionally susceptible to SARS-CoV-2, developing few or no clinical signs. Epidemiological surveillance of SARS-CoV-2 in dogs requires testing to distinguish it from other canine coronaviruses. In the last year, significant advances have been made in the diagnosis of SARS-CoV-2, allowing...

Descripción completa

Detalles Bibliográficos
Autores principales: Laidoudi, Younes, Sereme, Youssouf, Medkour, Hacène, Watier-Grillot, Stéphanie, Scandola, Pierre, Ginesta, Jacques, Andréo, Virginie, Labarde, Claire, Comtet, Loïc, Pourquier, Philippe, Raoult, Didier, Marié, Jean-Lou, Davoust, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327341/
https://www.ncbi.nlm.nih.gov/pubmed/34377760
http://dx.doi.org/10.1016/j.onehlt.2021.100293
_version_ 1783732055070212096
author Laidoudi, Younes
Sereme, Youssouf
Medkour, Hacène
Watier-Grillot, Stéphanie
Scandola, Pierre
Ginesta, Jacques
Andréo, Virginie
Labarde, Claire
Comtet, Loïc
Pourquier, Philippe
Raoult, Didier
Marié, Jean-Lou
Davoust, Bernard
author_facet Laidoudi, Younes
Sereme, Youssouf
Medkour, Hacène
Watier-Grillot, Stéphanie
Scandola, Pierre
Ginesta, Jacques
Andréo, Virginie
Labarde, Claire
Comtet, Loïc
Pourquier, Philippe
Raoult, Didier
Marié, Jean-Lou
Davoust, Bernard
author_sort Laidoudi, Younes
collection PubMed
description Dogs are occasionally susceptible to SARS-CoV-2, developing few or no clinical signs. Epidemiological surveillance of SARS-CoV-2 in dogs requires testing to distinguish it from other canine coronaviruses. In the last year, significant advances have been made in the diagnosis of SARS-CoV-2, allowing its surveillance in both human and animal populations. Here, using ELISA and automated western blotting (AWB) assays, we performed a longitudinal study on 809 apparently healthy dogs from different regions of France to investigate anti-SARS-CoV-2 antibodies. There were three main groups: (i) 356 dogs sampled once before the pandemic, (ii) 235 dogs sampled once during the pandemic, and (iii) 218 dogs, including 82 dogs sampled twice (before and during the pandemic), 125 dogs sampled twice during the pandemic and 11 dogs sampled three times (once before and twice during the pandemic). Using ELISA, seroprevalence was significantly higher during the pandemic [5.5% (25/453)] than during the pre-pandemic period [1.1% (5/449)]. Among the 218 dogs sampled twice, at least 8 ELISA-seroconversions were observed. ELISA positive pre-pandemic sera were not confirmed in serial tests by AWB, indicating possible ELISA cross-reactivity, probably with other canine coronaviruses. A significant difference was observed between these two serological tests (Q = 88, p = 0.008). A clear correlation was observed between SARS-CoV-2 seroprevalence in dogs and the incidence of SARS-CoV-2 infection in human population from the same area. AWB could be used as a second line assay to confirm the doubtful and discrepant ELISA results in dogs. Our results confirm the previous experimental models regarding the susceptibility of dogs to SARS-CoV-2, suggesting that viral transmission from and between dogs is weak or absent. However, the new variants with multiple mutations could adapt to dogs; this hypothesis cannot be ruled out in the absence of genomic data on SARS-CoV-2 from dogs.
format Online
Article
Text
id pubmed-8327341
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83273412021-08-09 SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay Laidoudi, Younes Sereme, Youssouf Medkour, Hacène Watier-Grillot, Stéphanie Scandola, Pierre Ginesta, Jacques Andréo, Virginie Labarde, Claire Comtet, Loïc Pourquier, Philippe Raoult, Didier Marié, Jean-Lou Davoust, Bernard One Health Research Paper Dogs are occasionally susceptible to SARS-CoV-2, developing few or no clinical signs. Epidemiological surveillance of SARS-CoV-2 in dogs requires testing to distinguish it from other canine coronaviruses. In the last year, significant advances have been made in the diagnosis of SARS-CoV-2, allowing its surveillance in both human and animal populations. Here, using ELISA and automated western blotting (AWB) assays, we performed a longitudinal study on 809 apparently healthy dogs from different regions of France to investigate anti-SARS-CoV-2 antibodies. There were three main groups: (i) 356 dogs sampled once before the pandemic, (ii) 235 dogs sampled once during the pandemic, and (iii) 218 dogs, including 82 dogs sampled twice (before and during the pandemic), 125 dogs sampled twice during the pandemic and 11 dogs sampled three times (once before and twice during the pandemic). Using ELISA, seroprevalence was significantly higher during the pandemic [5.5% (25/453)] than during the pre-pandemic period [1.1% (5/449)]. Among the 218 dogs sampled twice, at least 8 ELISA-seroconversions were observed. ELISA positive pre-pandemic sera were not confirmed in serial tests by AWB, indicating possible ELISA cross-reactivity, probably with other canine coronaviruses. A significant difference was observed between these two serological tests (Q = 88, p = 0.008). A clear correlation was observed between SARS-CoV-2 seroprevalence in dogs and the incidence of SARS-CoV-2 infection in human population from the same area. AWB could be used as a second line assay to confirm the doubtful and discrepant ELISA results in dogs. Our results confirm the previous experimental models regarding the susceptibility of dogs to SARS-CoV-2, suggesting that viral transmission from and between dogs is weak or absent. However, the new variants with multiple mutations could adapt to dogs; this hypothesis cannot be ruled out in the absence of genomic data on SARS-CoV-2 from dogs. Elsevier 2021-07-18 /pmc/articles/PMC8327341/ /pubmed/34377760 http://dx.doi.org/10.1016/j.onehlt.2021.100293 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Paper
Laidoudi, Younes
Sereme, Youssouf
Medkour, Hacène
Watier-Grillot, Stéphanie
Scandola, Pierre
Ginesta, Jacques
Andréo, Virginie
Labarde, Claire
Comtet, Loïc
Pourquier, Philippe
Raoult, Didier
Marié, Jean-Lou
Davoust, Bernard
SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay
title SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay
title_full SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay
title_fullStr SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay
title_full_unstemmed SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay
title_short SARS-CoV-2 antibodies seroprevalence in dogs from France using ELISA and an automated western blotting assay
title_sort sars-cov-2 antibodies seroprevalence in dogs from france using elisa and an automated western blotting assay
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327341/
https://www.ncbi.nlm.nih.gov/pubmed/34377760
http://dx.doi.org/10.1016/j.onehlt.2021.100293
work_keys_str_mv AT laidoudiyounes sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT seremeyoussouf sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT medkourhacene sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT watiergrillotstephanie sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT scandolapierre sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT ginestajacques sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT andreovirginie sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT labardeclaire sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT comtetloic sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT pourquierphilippe sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT raoultdidier sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT mariejeanlou sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay
AT davoustbernard sarscov2antibodiesseroprevalenceindogsfromfranceusingelisaandanautomatedwesternblottingassay